Immuron Ltd.
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on developing and commercializing a novel class of specifically targeted polyclonal antibodies. The company aims to address significant unmet medical needs, particularly in treating gastrointestinal disorders caused by pathogenic bacteria. Immuron has established partnerships with leading research institutions and companies to enhance its product development and manufacturing capabilities. The company is currently advancing its drug candidates through clinical development, targeting conditions such as Campylobacteriosis, recurrent Clostridiodes difficile infections, and travelers’ diarrhea. Immuron is also engaged in various scientific studies and collaborations to further its research and product efficacy. The company has a proprietary technology platform and is committed to transforming treatment paradigms for gastrointestinal health.
Industries
N/A
Nr. of Employees
small (1-50)
Immuron Ltd.
Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Patents
Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease
US-10144775-B2
View DetailsComposition and method for the treatment and prevention of enteric bacterial infections
US-8637025-B2
View Details
Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease
US-10144775-B2
View DetailsComposition and method for the treatment and prevention of enteric bacterial infections
US-8637025-B2
View DetailsProducts
Travelan
An oral caplet formulation containing hyperimmune bovine colostrum powder with targeted polyclonal antibodies raised against enterotoxigenic E. coli and other enteric bacteria; indicated in some jurisdictions to reduce risk of travellers' diarrhoea and available as a consumer health product through pharmacies and online retailers.
Protectyn
A colostrum-derived oral formulation enriched in anti-LPS antibodies produced from immunized cattle, supplied for digestive and liver support through practitioner channels and online in selected markets.
Travelan
An oral caplet formulation containing hyperimmune bovine colostrum powder with targeted polyclonal antibodies raised against enterotoxigenic E. coli and other enteric bacteria; indicated in some jurisdictions to reduce risk of travellers' diarrhoea and available as a consumer health product through pharmacies and online retailers.
Protectyn
A colostrum-derived oral formulation enriched in anti-LPS antibodies produced from immunized cattle, supplied for digestive and liver support through practitioner channels and online in selected markets.
Services
Manufacture and distribution of orally administered colostrum-derived immunotherapeutic and consumer health products for gastrointestinal use, sold through pharmacies, practitioner channels and e-commerce in multiple countries.
Partnerships with academic groups, government research bodies, defence research organisations and contract research organisations to support preclinical programs, GLP studies, vaccine production and clinical trials.
Manufacture and distribution of orally administered colostrum-derived immunotherapeutic and consumer health products for gastrointestinal use, sold through pharmacies, practitioner channels and e-commerce in multiple countries.
Partnerships with academic groups, government research bodies, defence research organisations and contract research organisations to support preclinical programs, GLP studies, vaccine production and clinical trials.
Expertise Areas
- Oral passive immunotherapy using hyperimmune bovine colostrum-derived polyclonal antibodies
- Antigen and immunogen design for enteric bacterial pathogens
- Preclinical development including GLP toxicology and animal challenge models
- Clinical trial management including randomized controlled trials and controlled human infection models
Key Technologies
- Hyperimmune bovine colostrum-derived polyclonal antibody production
- Antigen design targeting LPS, flagella, colonisation factors and toxins
- Lyophilization (freeze-drying) and oral dosage form manufacturing
- cGMP bioprocessing and CMC workflows
News & Updates
Immuron reports record half yearly sales for its product Travelan, indicating strong market performance and demand.
Immuron has filed a pre-investigational new drug application with the U.S. FDA for a new treatment targeting Clostridioides difficile infections.
Immuron's Partnership with Synlait
Immuron collaborates with Synlait for the production of hyper immune bovine colostrum powder, ensuring high quality control and safety standards.
Immuron's Longstanding Partnership with the University of Melbourne
Immuron has a long-standing partnership with the University of Melbourne for research that led to the commercialization of Travelan.
Immuron and Tréidlia Biovet Collaboration
Immuron has partnered with Tréidlia Biovet since 2003 for the manufacture of ETEC vaccines, enhancing its veterinary vaccine offerings.
IMM-124E is the active pharmaceutical ingredient used to manufacture both Travelan® & Protectyn®. Randomized control trials showed protection of up to 90% against infection with E.coli (ETEC) and the development of Travelers’ Diarrhea.
Immuron reports record half yearly sales for its product Travelan, indicating strong market performance and demand.
Immuron has filed a pre-investigational new drug application with the U.S. FDA for a new treatment targeting Clostridioides difficile infections.
Immuron's Partnership with Synlait
Immuron collaborates with Synlait for the production of hyper immune bovine colostrum powder, ensuring high quality control and safety standards.
Immuron's Longstanding Partnership with the University of Melbourne
Immuron has a long-standing partnership with the University of Melbourne for research that led to the commercialization of Travelan.
Immuron and Tréidlia Biovet Collaboration
Immuron has partnered with Tréidlia Biovet since 2003 for the manufacture of ETEC vaccines, enhancing its veterinary vaccine offerings.
IMM-124E is the active pharmaceutical ingredient used to manufacture both Travelan® & Protectyn®. Randomized control trials showed protection of up to 90% against infection with E.coli (ETEC) and the development of Travelers’ Diarrhea.